{"id":"effe2229-340b-4d42-bbaa-5ceed51ea610","name":"Johnson and Johnson MedTech","slug":"johnson-johnson-medtech","description":"Johnson and Johnson MedTech is the medical devices division of Johnson and Johnson, developing the Ottava robotic surgical system for soft-tissue surgery. Ottava received FDA De Novo authorization in 2026, positioning it as a competitor to Intuitive Surgical's da Vinci. Nearly six years from first unveiling to FDA clearance.","status":"active","founded":1886,"hq":"New Brunswick, NJ, USA","fundingTotal":null,"type":"hardware","reviewStatus":"reviewed","lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://www.reuters.com/business/healthcare-pharmaceuticals/johnson-johnsons-robotic-surgery-device-gets-us-fda-marketing-authorization-2026-07-22/","title":"Johnson and Johnson's robotic surgery device gets U.S. FDA marketing authorization","sourceName":"Reuters","publishedAt":"2026-07-22"}],"keyFacts":[{"label":"FDA clearance","value":"De Novo authorization for Ottava, July 22, 2026"},{"label":"Product","value":"Ottava table-integrated robotic surgical system"},{"label":"HQ","value":"New Brunswick, NJ, USA"},{"label":"Parent","value":"Johnson and Johnson (NYSE JNJ)"},{"label":"FDA","value":"De Novo authorization for general surgery procedures"},{"label":"Competitor","value":"Intuitive Surgical da Vinci"},{"label":"Timeline","value":"First unveiled ~2020, IDE approval late 2025, FDA De Novo 2026"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-07-23T13:20:44.413Z","updatedAt":"2026-07-23T13:52:10.495Z","jsonLd":{"@context":"https://schema.org","@type":"Organization","@id":"https://registry.deploy.report/companies/johnson-johnson-medtech","url":"https://registry.deploy.report/companies/johnson-johnson-medtech","name":"Johnson and Johnson MedTech","description":"Johnson and Johnson MedTech is the medical devices division of Johnson and Johnson, developing the Ottava robotic surgical system for soft-tissue surgery. Ottava received FDA De Novo authorization in 2026, positioning it as a competitor to Intuitive Surgical's da Vinci. Nearly six years from first unveiling to FDA clearance.","identifier":"effe2229-340b-4d42-bbaa-5ceed51ea610","foundingDate":"1886","address":"New Brunswick, NJ, USA","publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":null,"lifecycle_state":null,"architectural_position":{"cohort":null,"sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":1,"primary_source_types":["secondary-established-publication"]}}}